Prostate cancer deaths in UK hit record high of over 12,000 in 2017
Disease is most common cancer in men in UK but rise is largely due to ageing population
Related Articles
Nanostics and Protean BioDiagnostics Partner to Launch CDX Prostate for Men at Risk of Having Aggressive Prostate Cancer in the United States
Nanostics and Protean partner to offer CDX Prostate risk score as a diagnostic tool to men suspected of having aggressive prostate cancer in the USA.
The Indispensable Role of Pathologists
Dr. Tony Magliocco of the Moffit Cancer Center joins us to discuss the indepensible role of pathologists in precision medicine and the importance of technology…
Cancer of Unknown Primary – what does it mean?
Anthony Magliocco, MD is a cancer expert with over 30 years of experience.In this video he explains why someone might be diagnosed with a ‘cancer…
Protean MAPS™ Improves the Delivery of Precision Health Information to Community Oncology Practices — Protean BioDx
Protean and Roche have created a novel project to accelerate access to precision oncology for community based oncology programs.
Dyson spheres: Could alien megastructures exist in the Milky Way? Scientists found 7 places to look | CNN
New research suggests stars in the Milky Way give off infrared heat expected from Dyson spheres, which physicist Freeman Dyson theorized could be created by…
Cancer Informant
Cancer Informant is a podcast made to inform cancer patients and their loved ones about their options for cancer testing and treatment. Dr. Tony Magliocco…
How is prostate cancer detected? #prostatecancer #cancerscreening
Learn more about how prostate cancer is detected, risk factors, and treatments on our full video. Watch the full video on prostate cancer by clicking…
Aventa Genomics introduces NGS test for solid tumours
Aventa Genomics has launched its next-generation sequencing (NGS) test, Aventa FusionPlus, to identify gene fusions and translocations.
Aventa Genomics Announces Launch of Aventa FusionPlus, the First 3D Genomics Clinical Test for Patients with Solid Cancers
Aventa Genomics, a joint venture of Arima Genomics and Protean BioDiagnostics, launched the Aventa FusionPlus test for patients with solid cancers.
Aventa Genomics introduces NGS test for solid tumours
Aventa Genomics has launched its next-generation sequencing (NGS) test, Aventa FusionPlus, to identify gene fusions and translocations.